Synlogic Reports Q4 Results, Shares Down 3%
<p><a href='https://financialmodelingprep.com/financial-summary/SYBX'>Synlogic, Inc. (NASDAQ:SYBX) </a>shares were trading 3% lower Friday afternoon following the company’s Q4 results. </p>
<p>The company has several clinical updates on deck for 2022— starting with initial results for SYNB1934 in PKU in the first half of the year—which is expected to inform a product candidate selection for a planned pivotal trial in the second half of the year. </p>
<p>With shares trading near cash, analysts at Oppenheimer see an attractive buying opportunity ahead of upcoming readouts.</p>

NASDAQ:SYBX